Samsung Unit Attacks Takeda's Entyvio IP To Clear Biosimilar
A Samsung unit has urged a London judge to nix a Takeda unit's patents protecting its Entyvio drug, arguing that the American rival's treatment for Crohn's disease was always invalid. ...To view the full article, register now.
Already a subscriber? Click here to view full article